WO2001030391A3 - Pharmaceutical composition containing midazolam - Google Patents
Pharmaceutical composition containing midazolam Download PDFInfo
- Publication number
- WO2001030391A3 WO2001030391A3 PCT/IB2000/001525 IB0001525W WO0130391A3 WO 2001030391 A3 WO2001030391 A3 WO 2001030391A3 IB 0001525 W IB0001525 W IB 0001525W WO 0130391 A3 WO0130391 A3 WO 0130391A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- composition containing
- midazolam
- containing midazolam
- cyclodextrin
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Otolaryngology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU79375/00A AU7937500A (en) | 1999-10-27 | 2000-10-24 | Pharmaceutical composition containing midazolam |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA99/6756 | 1999-10-27 | ||
ZA996756 | 1999-10-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001030391A2 WO2001030391A2 (en) | 2001-05-03 |
WO2001030391A3 true WO2001030391A3 (en) | 2001-12-20 |
Family
ID=25587963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2000/001525 WO2001030391A2 (en) | 1999-10-27 | 2000-10-24 | Pharmaceutical composition containing midazolam |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU7937500A (en) |
WO (1) | WO2001030391A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9803240D0 (en) | 1998-09-24 | 1998-09-24 | Diabact Ab | A pharmaceutical composition having a rapid action |
GB0130964D0 (en) * | 2001-12-24 | 2002-02-13 | Special Products Ltd | Pharmaceutical composition |
GB0400804D0 (en) | 2004-01-14 | 2004-02-18 | Innoscience Technology Bv | Pharmaceutical compositions |
GB0423800D0 (en) * | 2004-10-27 | 2004-12-01 | Orexo Ab | New pharmaceutical formulations |
GB0720716D0 (en) * | 2007-10-23 | 2007-12-05 | York Pharma Plc | Novel formulation |
EP2106786A1 (en) * | 2008-04-04 | 2009-10-07 | Roewer, Norbert, Univ.-Prof. Dr. med. | Pharmaceutical preparation comprising permethylated cyclodextrin |
GB2481407B (en) | 2010-06-22 | 2012-05-23 | Special Products Ltd | A rapid onset liquid midazolam composition for buccal administration |
DK2919791T3 (en) | 2012-11-15 | 2017-07-17 | Sapiotec Gmbh | Delphinidine complex as antiflogistic or immunosuppressant active substance |
KR20150107742A (en) | 2012-12-11 | 2015-09-23 | 자피오텍 게엠베하 | Delphinidin for combating melanoma cells |
US20210379080A1 (en) | 2018-12-18 | 2021-12-09 | Cipla Limited | Intranasal Formulation |
CN113209013B (en) * | 2021-06-24 | 2023-04-07 | 新疆特丰药业股份有限公司 | Midazolam liquid preparation and preparation method and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994002518A1 (en) * | 1992-07-27 | 1994-02-03 | The University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
EP0657176A2 (en) * | 1993-12-06 | 1995-06-14 | Takeda Chemical Industries, Ltd. | Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility |
WO1999042111A1 (en) * | 1998-02-23 | 1999-08-26 | Cyclops, Ehf. | High-energy cyclodextrin complexes |
-
2000
- 2000-10-24 WO PCT/IB2000/001525 patent/WO2001030391A2/en active Application Filing
- 2000-10-24 AU AU79375/00A patent/AU7937500A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994002518A1 (en) * | 1992-07-27 | 1994-02-03 | The University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
EP0657176A2 (en) * | 1993-12-06 | 1995-06-14 | Takeda Chemical Industries, Ltd. | Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility |
WO1999042111A1 (en) * | 1998-02-23 | 1999-08-26 | Cyclops, Ehf. | High-energy cyclodextrin complexes |
Non-Patent Citations (5)
Title |
---|
LOFTSSON T. ET AL: "Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 212, January 2001 (2001-01-01), pages 29 - 40, XP001023911 * |
MERKUS F W H M ET AL: "CYCLODEXTRINS IN NASAL DRUG DELIVERY", ADVANCED DRUG DELIVERY REVIEWS, AMSTERDAM, NL, vol. 36, no. 1, 1 March 1999 (1999-03-01), pages 41 - 57, XP001023913, ISSN: 0169-409X * |
ROELOFSE JA.: "Intranasal midazolam spray in adults-pharmacokinetics and clinical use", SAJAA, June 2000 (2000-06-01), XP001025564 * |
SIGURJÓNSDÓTTIR J. F. ET AL: "Formulation and preliminary clinical testing of midazolam-cyclodextrin nasal spray", PROCEED. INT'L SYMP. CONTROL. REL. BIOACT. MATER, vol. 27, 2000, pages 700 - 701, XP001025500 * |
THUM P ET AL: "MIDAZOLAM GIVEN AS AN INTRANASAL SPRAY IN CHILDREN", BRITISH JOURNAL OF ANAESTHESIA, BJM PUBLISHING GROUP, LONDON, GB, vol. 81, no. 1, July 1998 (1998-07-01), pages 100 - 101, XP001023963, ISSN: 0007-0912 * |
Also Published As
Publication number | Publication date |
---|---|
AU7937500A (en) | 2001-05-08 |
WO2001030391A2 (en) | 2001-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0302086A2 (en) | Oral pharmaceutical composition with a delayed action and process for its preparation | |
WO1998025613A3 (en) | Galenic composition containing opioid antagonists | |
AU2331801A (en) | Improved pharmaceutical compositions for poorly soluble drugs | |
HK1029060A1 (en) | Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin | |
EP1246608A4 (en) | Pharmaceutical formulations for the delivery of drugs having low aqueous solubility | |
CA2289202A1 (en) | Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent | |
HK1046134A1 (en) | Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them. | |
WO2001030391A3 (en) | Pharmaceutical composition containing midazolam | |
WO2001032181A3 (en) | Pharmaceutical compositions containing a fluoroquinolone antibiotic drug and xanthan gum | |
CA2270177A1 (en) | Transdermal administration of ment | |
PL346764A1 (en) | New oral formulation for 5-ht4 | |
MY135548A (en) | Aqueous preparation containing oligopeptides and etherified cyclodextrin | |
AU1735001A (en) | Cyclodextrin-containing pharmaceutical composition | |
WO2000076528A3 (en) | Pharmaceutical preparation containing proteins | |
AU4061599A (en) | Aqueous preparations containing hardly soluble drug | |
ZA200203078B (en) | Ciclesonide-containing aqueous pharmaceutical composition. | |
AU1776801A (en) | Modular targeted liposomal delivery system | |
CA2305359A1 (en) | Drug delivery system | |
WO2002076376A3 (en) | A stable pharmaceutical composition of pravastatin | |
AU4929400A (en) | Pharmaceutical compositions for oral administration of phloroglucinol and preparation thereof | |
AU5072000A (en) | Pharmaceutical composition for nasally administering water-soluble active substances | |
CA2376847A1 (en) | Complex of eletriptan and a cyclodextrin derivative | |
AU5818096A (en) | Topical aciclovir preparation | |
WO2001021140A3 (en) | Cosmetic and/or pharmaceutical preparations | |
AU1584800A (en) | Immuno-active, anti-cancer and pharmacologically active polysaccharide compoundsand pharmaceutical compositions containing the polysaccharide compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |